| Tyler Reinthaler, | |
|
3520 Route 130, Suite 1, Irwin, PA 15642-1438 | |
| (724) 744-2043 | |
| Not Available |
| Full Name | Tyler Reinthaler |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 9 Years |
| Location | 3520 Route 130, Irwin, Pennsylvania |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1770961690 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | MD464197 (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Amedisys Home Health Of Pa | Uniontown, PA | Home health agency |
| Upmc Home Healthcare | Seven fields, PA | Home health agency |
| Magee Womens Hospital Of Upmc Health System | Pittsburgh, PA | Hospital |
| Upmc Presbyterian Shadyside | Pittsburgh, PA | Hospital |
| Upmc East | Monroeville, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Upmc Community Medicine Inc | 2062318975 | 690 |
News Archive
Over 93 percent of heart attack patients are receiving stents within the guideline-recommended threshold of 90 minutes after arriving at the hospital, with the median time to stenting only 59 minutes, according to a broad report on trends in heart disease care from the American College of Cardiology's National Cardiovascular Data Registry published in the Journal of the American College of Cardiology.
Researchers led by the University of Birmingham have found a potential new target to treat inflammatory disease.
Peregrine Pharmaceuticals, Inc. today announced that the U.S. Patent and Trademark Office has issued U.S. Patent Number 7,611,704, which includes broad claims covering anti-viral uses of phosphatidylserine (PS)-targeting antibodies including Peregrine's lead clinical compound, bavituximab. PS is a unique marker exposed on the surface of virally infected cells that can be targeted to treat a broad spectrum of virus infections.
UI Heart Care researchers are among the first in the nation to evaluate the effectiveness of cardiac resynchronization therapy (CRT) devices to reduce the risk of mortality and hospitalization in advanced heart failure patients.
The Huntington Study Group (HSG), under the leadership of Ray Dorsey, M.D. with Johns Hopkins Medical and Diana Rosas, M.D. with Massachusetts General Hospital, is conducting a clinical trial in Huntington's disease (HD) throughout the United States and Australia, "A randomized, double-blind, placebo-controlled, study to assess the safety and tolerability, and efficacy of PBT2 in patients with early to mid-stage Huntington's disease" comparing a 100 mg dose or 250 mg dose versus placebo.
› Verified 3 days ago
| Entity Name | Upmc Community Medicine Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1558976092 PECOS PAC ID: 2062318975 Enrollment ID: O20040217000388 |
News Archive
Over 93 percent of heart attack patients are receiving stents within the guideline-recommended threshold of 90 minutes after arriving at the hospital, with the median time to stenting only 59 minutes, according to a broad report on trends in heart disease care from the American College of Cardiology's National Cardiovascular Data Registry published in the Journal of the American College of Cardiology.
Researchers led by the University of Birmingham have found a potential new target to treat inflammatory disease.
Peregrine Pharmaceuticals, Inc. today announced that the U.S. Patent and Trademark Office has issued U.S. Patent Number 7,611,704, which includes broad claims covering anti-viral uses of phosphatidylserine (PS)-targeting antibodies including Peregrine's lead clinical compound, bavituximab. PS is a unique marker exposed on the surface of virally infected cells that can be targeted to treat a broad spectrum of virus infections.
UI Heart Care researchers are among the first in the nation to evaluate the effectiveness of cardiac resynchronization therapy (CRT) devices to reduce the risk of mortality and hospitalization in advanced heart failure patients.
The Huntington Study Group (HSG), under the leadership of Ray Dorsey, M.D. with Johns Hopkins Medical and Diana Rosas, M.D. with Massachusetts General Hospital, is conducting a clinical trial in Huntington's disease (HD) throughout the United States and Australia, "A randomized, double-blind, placebo-controlled, study to assess the safety and tolerability, and efficacy of PBT2 in patients with early to mid-stage Huntington's disease" comparing a 100 mg dose or 250 mg dose versus placebo.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Tyler Reinthaler, 3520 Route 130, Suite 1, Irwin, PA 15642-1438 Ph: () - | Tyler Reinthaler, 3520 Route 130, Suite 1, Irwin, PA 15642-1438 Ph: (724) 744-2043 |
News Archive
Over 93 percent of heart attack patients are receiving stents within the guideline-recommended threshold of 90 minutes after arriving at the hospital, with the median time to stenting only 59 minutes, according to a broad report on trends in heart disease care from the American College of Cardiology's National Cardiovascular Data Registry published in the Journal of the American College of Cardiology.
Researchers led by the University of Birmingham have found a potential new target to treat inflammatory disease.
Peregrine Pharmaceuticals, Inc. today announced that the U.S. Patent and Trademark Office has issued U.S. Patent Number 7,611,704, which includes broad claims covering anti-viral uses of phosphatidylserine (PS)-targeting antibodies including Peregrine's lead clinical compound, bavituximab. PS is a unique marker exposed on the surface of virally infected cells that can be targeted to treat a broad spectrum of virus infections.
UI Heart Care researchers are among the first in the nation to evaluate the effectiveness of cardiac resynchronization therapy (CRT) devices to reduce the risk of mortality and hospitalization in advanced heart failure patients.
The Huntington Study Group (HSG), under the leadership of Ray Dorsey, M.D. with Johns Hopkins Medical and Diana Rosas, M.D. with Massachusetts General Hospital, is conducting a clinical trial in Huntington's disease (HD) throughout the United States and Australia, "A randomized, double-blind, placebo-controlled, study to assess the safety and tolerability, and efficacy of PBT2 in patients with early to mid-stage Huntington's disease" comparing a 100 mg dose or 250 mg dose versus placebo.
› Verified 3 days ago
Dr. Mark C Gottron, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 905 Spruce St, Suite 201, Irwin, PA 15642 Phone: 724-864-9595 Fax: 724-864-9860 | |
Dr. Jawdat A Nikoula, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 905 Spruce St Ste 201, Irwin, PA 15642 Phone: 724-864-9595 Fax: 724-864-9860 | |
Robert P Zimmerman, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3520 Route 130 Ste 2002, Irwin, PA 15642 Phone: 724-744-6167 Fax: 724-744-6070 | |
Dr. Emilio Villegas, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 100 Pennsylvania Ave, Irwin, PA 15642 Phone: 724-863-1204 Fax: 724-863-9169 | |
Antoine Cawog, Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 422 Main St, Irwin, PA 15642 Phone: 724-864-4920 | |
Michael P Hahalyak, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 7546 Route 30, 1st Floor, Irwin, PA 15642 Phone: 724-765-1030 Fax: 724-765-1023 | |
Dr. James Y. Lim, M.D. Family Medicine Medicare: May Accept Medicare Assignments Practice Location: 905 Spruce St, Irwin, PA 15642 Phone: 724-864-9595 Fax: 724-864-9860 |